



INHERITED EYE DISORDERS TESTING REQUISITION

PATIENT INFORMATION (COMPLETE ONE FORM FOR EACH PERSON TESTED)

Patient Last Name		Patient First Name		MI	Date of Birth (MM / DD / YYYY)	
Address		City	State	Zip	Phone	
Accession #	Hospital / Medical Record #		Patient discharged from the hospital/facility: <input type="radio"/> Yes <input type="radio"/> No		Genetic Sex: <input type="radio"/> Female <input type="radio"/> Male <input type="radio"/> Unknown Gender identity (if different from above):	

REPORTING RECIPIENTS

Ordering Physician	Institution Name	
Email (Required for International Clients)	Phone	Fax

ADDITIONAL RECIPIENTS

Name	Email	Fax
Name	Email	Fax

PAYMENT (FILL OUT ONE OF THE OPTIONS BELOW)

☐ **SELF PAYMENT**

☐ Pay With Sample ☐ Bill To Patient

☐ **INSTITUTIONAL BILLING**

Institution Name	Institution Code	Institution Contact Name	Institution Phone	Institution Contact Email
------------------	------------------	--------------------------	-------------------	---------------------------

☐ **INSURANCE**

☐ Do Not Perform Test Until Patient is Aware of Out-Of-Pocket Costs (excludes prenatal testing)

REQUIRED ITEMS 1. Copy of the Front/Back of Insurance Card(s) 2. ICD10 Diagnosis Code(s) 3. Name of Ordering Physician 4. Insured Signature of Authorization

Name of Insured		Insured Date of Birth (MM / DD / YYYY)		Name of Insured		Insured Date of Birth (MM / DD / YYYY)	
Patient's Relationship to Insured		Phone of Insured		Patient's Relationship to Insured		Phone of Insured	
Address of Insured				Address of Insured			
City	State	Zip	City	State	Zip	City	State
Primary Insurance Co. Name		Primary Insurance Co. Phone		Secondary Insurance Co. Name		Secondary Insurance Co. Phone	
Primary Member Policy #		Primary Member Group #		Secondary Member Policy #		Secondary Member Group #	

By signing below, I hereby authorize Baylor Genetics to provide my insurance carrier any information necessary, including test results, for processing my insurance claim. I understand that I am responsible for any co-pay, co-insurance, and unmet deductible that the insurance policy dictates, as well as any amounts not paid by my insurance carrier for reasons including, but not limited to, non-covered and non-authorized services. I understand that I am responsible for sending Baylor Genetics any and all payments that I receive directly from my insurance company in payment for this test. Please note that Medicare does not cover routine screening tests.

Patient's Printed Name	Patient's Signature	Date (MM / DD / YYYY)
------------------------	---------------------	-----------------------

STATEMENT OF MEDICAL NECESSITY (REQUIRED)

This test is medically necessary for the risk assessment, diagnosis, or detection of a disease, illness, impairment, symptom, syndrome, or disorder. The results will determine my patient's medical management and treatment decisions. The person listed as the Ordering Physician is authorized by law to order the test(s) requested herein. I confirm that I have provided genetic testing information to the patient and they have consented to genetic testing.

Physician's Printed Name	Physician's Signature	Date (MM / DD / YYYY)
--------------------------	-----------------------	-----------------------



INHERITED EYE DISORDERS TESTING REQUISITION

Patient Last Name

Patient First Name

MI

Date of Birth (MM / DD / YYYY)

Genetic Sex

ETHNICITY

- ☐ African American ☐ Hispanic American ☐ Pacific Islander (Philippines, Micronesia, Malaysia, Indonesia)
- ☐ Ashkenazi Jewish ☐ Mennonite ☐ South Asian (India, Pakistan)
- ☐ East Asian (China, Japan, Korea) ☐ Middle Eastern (Saudi Arabia, Qatar, Iraq, Turkey) ☐ Southeast Asian (Vietnam, Cambodia, Thailand)
- ☐ Finnish ☐ Native American ☐ Southern European Caucasian (Spain, Italy, Greece)
- ☐ French Canadian ☐ Northern European Caucasian (Scandinavian, UK, Germany) ☐ Other (Specify): _____

INDICATION FOR TESTING (REQUIRED)

- ☐ Symptomatic (Summarize below) ☐ Symptomatic with Family History

- ☐ Asymptomatic

- ☐ Population Screening ☐ Positive Family History

Disease

Gene

Variant

ICD10 Diagnosis Code(s): _____

SAMPLE

SAMPLE TYPE

- ☐ Blood in EDTA-tube (purple-top) ☐ DNA
- ☐ Blood in Heparin-tube (green-top) ☐ Saliva
- ☐ Cultured Skin Fibroblast ☐ Skin Biopsy
- ☐ Other (Specify) _____ ☐ Tissue

NOTE: Extracted DNA/RNA will only be accepted if the isolation of nucleic acids for clinical testing occurs in a CLIA-certified laboratory or a laboratory meeting equivalent requirements as determined by the CAP and/or the CMS.

Blood should not be sent from patients who have had a bone marrow transplant or recent blood transfusion

Date of Collection (MM/DD/YY)

TESTING OPTIONS

- ☐ Targeted Sequencing for Known Familial Mutation (If selected, specify test code and gene below and complete section to the right)

Test Code

Gene

- ☐ Full Gene Sequencing
- ☐ Deletion/ Duplication Analysis

FOR TARGETED TESTING SELECTION ONLY

Proband Last Name

Proband First Name

Date of Birth (MM/DD/YY)

Relationship of Proband to Patient

Proband testing location (Select one)

- ☐ Baylor Genetics Lab# Family#

- ☐ Another laboratory
1. Attach a copy of the Proband test results
2. A positive control sample of the Proband is requested.
Please provide, if available.

INHERITED EYE DISORDERS TESTS

CYTOGENETIC TESTS

TEST CODE	TEST NAME	SAMPLE TYPE*	SPECIFY GENE OF INTEREST	SPECIFY REGION OF INTEREST
<input type="checkbox"/> 8665	Chromosomal Microarray Analysis (CMA) - HR + SNP Screen (Comprehensive)	BE, DNA, CF, SB, BUC		
<input type="checkbox"/> 8655	Chromosomal Microarray Analysis (CMA) - HR	BE, DNA, CF, SB, BUC		

MITOCHONDRIAL DNA (MTDNA) MUTATION SCREENS

TEST CODE	TEST NAME	SAMPLE TYPE*
<input type="checkbox"/> 2010	Advanced mtDNA Point Mutations and Deletions by Massively Parallel Sequencing (BCM-MitomeNGSSM)	BE, DNA, CF, T
<input type="checkbox"/> 2055	Comprehensive mtDNA Analysis by Massively Parallel Sequencing (BCM-MitomeNGSSM)	BE, DNA, CF, T

* Refer to Sample Specifications Table (page 5)



INHERITED EYE DISORDERS TESTING REQUISITION

Patient Last Name

Patient First Name

MI

Date of Birth (MM / DD / YYYY)

Genetic Sex

FISH STUDIES

MASSIVELY PARALLEL SEQUENCING (BCM-MITOMENGSSM) PANELS

TEST CODE	TEST NAME	SAMPLE TYPE*	TEST CODE	TEST NAME	SAMPLE TYPE*
<input type="checkbox"/> 20100	Albinism Panel (13 genes)	BE, DNA, CF, SA, BUC	<input type="checkbox"/> 5255	Primary Open Angle Glaucoma Panel (MYOC, OPTN)	BE, DNA, CF, SA, BUC
<input type="checkbox"/> 5260	Developmental Glaucoma Panel (8 genes)	BE, DNA, CF, SA, BUC	<input type="checkbox"/> 2140	Progressive External Ophthalmoplegia Panel (10 genes)	BE, DNA, CF, SA, BUC
<input type="checkbox"/> 5250	Familial Exudative Vitreoretinopathy Panel (FZD4, LRP5, NDP, and TSPAN12)	BE, DNA, CF, SA, BUC	<input type="checkbox"/> 2190	Retinitis Pigmentosa + RPGR orf15 by NGS (66 genes)	BE, DNA, CF, SA, BUC
<input type="checkbox"/> 5090	Leber Congenital Amaurosis Panel (19 genes)	BE, DNA, CF, SA, BUC	<input type="checkbox"/> 2195	Usher Syndrome Panel (9 genes)	BE, DNA, CF, SA, BUC

DNA COPY NUMBER ANALYSIS

TEST CODE	TEST NAME	SAMPLE TYPE*	SPECIFY GENE OF INTEREST			
<input type="checkbox"/> 2000	MitoMet*Plus aCGH Analysis	BE				
<input type="checkbox"/> 2001	Oligonucleotide Targeted Array Analysis (Single Target Gene)	BE				
<input type="checkbox"/> 2003	Oligonucleotide Targeted Array Analysis (Up to 5 Target Genes)	BE				

SINGLE GENE ANALYSIS

If a test is not found on this form, please obtain the test code from our website (www.BMGL.com) and write in the below space(s).

Test Code

Gene

Test Code

Gene

Test Code

Gene

Test Name

Test Name

Test Name

TEST CODE	TEST NAME	DISORDER	SAMPLE TYPE*
<input type="checkbox"/> 6603	ABCA4 Comprehensive (Seq. & Del/Dup Analysis)	ABCA4-Related Disorders	BE, DNA
<input type="checkbox"/> 2924	BEST1 Comprehensive (Seq. & Del/Dup Analysis)	BEST1-Related Disorders	BE, DNA
<input type="checkbox"/> 2419	CEP290 Comprehensive (Seq. & Del/Dup Analysis) CEP290	CEP290-Related Disorders	BE, DNA
<input type="checkbox"/> 6655	CDH23 Sequence Analysis	CDH23-Related Disorders	BE, DNA
<input type="checkbox"/> 6660	CLRN1 Sequence Analysis	CLRN1-Related Disorders	BE, DNA
<input type="checkbox"/> 7521	COL2A1 Comprehensive (Seq. & Del/Dup Analysis)	COL2A1-Related Disorders	BE, DNA
<input type="checkbox"/> 2389	CDHR1 Comprehensive (Seq. & Del/Dup Analysis)	Cone-Rod Dystrophy 15	BE, DNA
<input type="checkbox"/> 2849	CRB1 Comprehensive (Seq. & Del/Dup Analysis)	CRB1-Related Disorders	BE, DNA
<input type="checkbox"/> 5280	OAT Sequence Analysis	Gyrate Atrophy of Choroid and Retina	BE, DNA
<input type="checkbox"/> 2789	IMPDH1 Comprehensive (Seq. & Del/Dup Analysis)	IMPDH1-Related Disorders	BE, DNA
<input type="checkbox"/> 2394	LCA5 Comprehensive (Seq. & Del/Dup Analysis)	LCA5-Related Disorders	BE, DNA

* Refer to Sample Specifications Table (page 5)

Continued on next page



INHERITED EYE DISORDERS TESTING REQUISITION

Patient Last Name _____ Patient First Name _____ MI _____ Date of Birth (MM / DD / YYYY) _____ Genetic Sex _____

SINGLE GENE ANALYSIS CONTINUED

TEST CODE	TEST NAME	DISORDER	SAMPLE TYPE*
<input type="checkbox"/> 6039	OCRL Sequence Analysis	Lowe Syndrome	BE, DNA
<input type="checkbox"/> 2839	LRAT Comprehensive (Seq. & Del/Dup Analysis)	LRAT-Related Disorders	BE, DNA
<input type="checkbox"/> 6083	X-Linked, GPR143 Comprehensive (Seq. & Del/Dup Analysis)	Oculocutaneous Albinism	BE, DNA
<input type="checkbox"/> 3529	Type 3, OPA3 Comprehensive (Seq. & Del/Dup Analysis)	Optic Atrophy	BE, DNA
<input type="checkbox"/> 2414	ABHD12 Comprehensive (Seq. & Del/Dup Analysis)	Polyneuropathy, Hearing Loss, Ataxia, Retinitis Pigmentosa, and Cataract Disorder	BE, DNA
<input type="checkbox"/> 2959	RDH12 Comprehensive (Seq. & Del/Dup Analysis)	RDH12-Related Disorders	BE, DNA
<input type="checkbox"/> 2974	EYS Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE, DNA
<input type="checkbox"/> 2994	FAM161A Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE, DNA
<input type="checkbox"/> 2984	MERTK Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE, DNA
<input type="checkbox"/> 2459	PDE6B Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE, DNA
<input type="checkbox"/> 2399	PROM1 Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE, DNA
<input type="checkbox"/> 2939	PRPH2 Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE, DNA
<input type="checkbox"/> 2479	RGR Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE, DNA
<input type="checkbox"/> 2449	RP2 Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE, DNA
<input type="checkbox"/> 2359	RPGR Comprehensive (Seq. & Del/Dup Analysis)	Retinitis Pigmentosa	BE, DNA

* Refer to Sample Specifications Table (page 5)

Continued on next page

INHERITED EYE DISORDERS TESTING REQUISITION

Patient Last Name

Patient First Name

MI

/

/

Date of Birth (MM / DD / YYYY)

Genetic Sex

SINGLE GENE ANALYSIS CONTINUED

TEST CODE	TEST NAME	DISORDER	SAMPLE TYPE*
<input type="checkbox"/> 2934	RPE65 Comprehensive (Seq. & Del/Dup Analysis)	RPE65-Related Disorders	BE, DNA
<input type="checkbox"/> 2899	PRKCG Comprehensive (Seq. & Del/Dup Analysis)	Spinocerebellar Ataxia 14 (SCA)	BE, DNA
<input type="checkbox"/> 6650	USH2A Sequence Analysis	USH2A-Related Disorders	BE, DNA

* Refer to Sample Specifications Table below

SAMPLE SPECIFICATIONS TABLE

ABBREVIATION	SAMPLE NAME	RECOMMENDED AMOUNT		SHIPPING INSTRUCTIONS	SPECIAL NOTES
		(2 YRS - ADULT)	(NEWBORN - 2 YRS)		
BE	Blood in EDTA tube (purple-top)	3 - 5 cc	3 cc	Ship at room temperature in an insulated container by overnight courier. Do not heat or freeze.	For clarification or follow-up of CMA results, sodium heparin (green top) tubes are highly recommended. Send 3 - 5 cc (adults/children) and 1 - 2 cc (infant<2 years).
CF	Cultured Skin Fibroblast	2 T25 flasks		Ship at room temperature in an insulated container by overnight courier. Do not heat or freeze.	Send 2 T25 flasks at 80 - 100% confluence
DNA	DNA, Extracted	At least 20 ug of purified DNA		Ship at room temperature in an insulated container by overnight courier. Do not heat or freeze.	Minimal concentration of 50 ng / uL; A260 / A280 of ~1.7 - 2.0
SA	Saliva	See Special Notes		Ship at room temperature in an insulated container by overnight courier. Do not heat or freeze.	Collected with Oragene•DX DNA Self-Collection Kit
T	Tissue	50 mg		Ship frozen sample in insulated container with 3 - 5 lbs. of dry ice by overnight courier.	Tissue should be flash frozen in liquid nitrogen at collection with no media added, and stored at -80° C.
SB	Skin Biopsy	5mm ³		Ship at ambient temperature (18-25° C / 64-77° F). Protect paraffin tissue from excessive heat. Ship in cooled container during summer months.	Collect skin from a central location (e.g., buttock or upper thigh) rather than from a distal location (e.g., foot) to enhance cell viability. Place sample in a separate sterile container with RPMI media. In the absence of RPMI media, place sample in a sterile container with a small amount of sterile saline. Unacceptable Conditions: Specimens placed in formalin or other fixatives.



INFORMED CONSENT FOR INHERITED EYE DISORDERS TESTING

Patient Last Name

Patient First Name

MI

Date of Birth (MM / DD / YYYY)

Genetic Sex

TEST INFORMATION

This consent form will provide you with information regarding genetic testing, which you should discuss with your healthcare provider or a genetic counselor. To assist you in understanding the reason for this testing, we have provided information about the testing process and potential results below.

The purpose of genetic testing is to determine if a genetic disease may be present or if there is an increased risk for a genetic disease to occur in a patient or their family. DNA is the genetic material that we receive from our parents. Genes are made of DNA and are the instructions for maintaining the health of our body. Each person has a unique set of DNA and most of the differences in our DNA do not impact our health. Genetic testing analyzes DNA to find any abnormal changes (mutations also called variants) that might cause disease, make it more likely to develop disease, and/or increase the chance of having a child affected by disease.

The testing ordered by your healthcare provider can determine if you or your child have a variant associated with a genetic disease. "Your child" can also mean your unborn child, for the purposes of this consent.

Depending on why genetic testing is needed, you might be tested for:

- A known variant that has already been found in your family
- A single gene or variant that causes a specific, suspected disease.
- Multiple genes at the same time. These genes might cause similar diseases or might cause diseases that are unrelated to each other.
- Multiple types of testing that each test for different variants.

RESULTS

There are several types of test results that may be reported including:

- **Positive:** Positive or "abnormal" results mean there is a change in the DNA found that is related to your/your child's medical issues or that you/your child are at an increased risk of developing a disease in the future. It is possible to test positive for more than one variant. Positive results might include pathogenic variants (variants known to be associated with disease) and likely pathogenic variants (variants that are likely to be associated with disease).
- **Negative:** Negative or "normal" results mean no relevant variants related to your/your child's medical issues were detected or that you/your child are not expected to be at an increased risk for developing a disease in the future. This might indicate that there are no variants associated with disease in the gene(s) tested. Genetic testing, while highly accurate, might not detect a variant present in the gene(s) tested. This can be due to limitations of the information available about the gene(s) being tested, or limitations of the testing technology.
- **Variant of Uncertain Significance:** Testing can detect variant(s) in DNA which we do not yet fully understand. These are also referred to as variants of uncertain significance (VUS). Additional testing may be recommended for you or your family if a VUS is identified in a gene that may be associated with your/your child's medical condition.
- **Secondary / Incidental Findings:** Testing can sometimes detect a variant in a person's DNA unrelated to the reason for testing. If this variant is expected to have medical or reproductive significance, it is called a secondary or incidental finding.

CONSIDERATIONS AND LIMITATIONS

- This consent form cannot be used for whole exome sequencing (WES), whole genome sequencing (WGS), or Huntington's disease testing. These tests have specific consents that are located at <https://www.baylorgenetics.com/consent/>.
- Results may indicate you have a genetic disease, are at increased risk to develop a genetic disease, and/or be at an increased risk to have a child with a genetic disease. It is important to understand that genetic tests, even if negative, cannot rule out every variant. It is not possible to exclude risks for all genetic diseases for you and your family members.
- Depending on the type of genetic testing performed and the results, additional genetic testing or other testing may be needed to fully understand the likelihood of your developing the disease or the severity of the disease. This additional testing might be needed for you/your child or other members of your family.
- It is recommended that you discuss genetic testing with your healthcare provider or genetic counselor before signing this consent and again after results are made available.
- It may not always be possible to complete testing, as sometimes the sample does not have enough DNA to perform testing or other reasons. In these cases, another sample may need to be sent to the laboratory to perform testing.

PATIENT CONFIDENTIALITY AND SPECIMEN RETENTION

- If several family members are tested, the correct interpretation of the results depends on the information provided about the relationships amongst family members. In rare cases, genetic testing can reveal that the true biological relationships in a family are not as they were reported. If a difference is identified, it may be necessary to share this information with the healthcare provider who ordered the testing.

INFORMED CONSENT FOR INHERITED EYE DISORDERS TESTING

Patient Last Name Patient First Name MI Date of Birth (MM / DD / YYYY) Genetic Sex

PATIENT CONFIDENTIALITY AND SPECIMEN RETENTION (CONT.)

- Genetic testing is highly accurate, however in rare cases, inaccurate results may occur. Reasons for this include, but are not limited to, mislabeled samples, inaccurate reporting of clinical/medical information, or rare technical errors.
- If you sign this consent form, but you no longer wish to have your sample(s) tested, you can contact the healthcare provider who ordered the test to cancel the test. If you wish to cancel testing, the laboratory must be notified of the cancellation request before 5 PM CST the business day after the sample has begun testing. If the laboratory is not notified of your cancellation request until after this time, you will be charged for the full cost of the test.
- Only Baylor Genetics and Baylor Genetics contracted partners will have access to the sample(s) provided to conduct the requested testing. Results will only be released to the following person(s): (i) a licensed healthcare provider, (ii) those authorized in writing, (iii) the patient or their personal representative, and (iv) those allowed access to test results by law. I understand that I have the right to access any test results directly from Baylor Genetics by providing a written request. I also understand that laboratory raw data, while not routinely released as part of the testing process, can be requested by providing a written request or HIPAA Authorization Form.
- In rare cases, persons with genetic diagnoses have experienced problems with insurance coverage and employment. The U.S. Federal Government has enacted several laws that prohibit discrimination based on genetic test results by health insurance companies and employers. In addition, these laws prohibit unauthorized disclosure of this information. For more information, you can visit www.genome.gov/10002077.
- Samples will be retained in the laboratory in accordance with the laboratory retention policy.
- After testing is complete, the de-identified submitted specimen may be used for test development and improvement, internal validation, quality assurance, and training purposes. DNA specimens are not returned to individuals or to referring health care providers unless specific prior arrangements have been made.
- Samples from residents of New York State will not be included in research studies without your written consent and will not be retained for more than 60 days after receipt of the sample. No tests other than those authorized shall be performed on the biological sample.
- By signing this consent form, I understand and agree that variants identified may also be submitted to public databases, such as ClinVar. Such submission serves to contribute knowledge to the medical community. I understand that limited clinical information is also required for the submission of information to ClinVar's database and further that the contents of this limited clinical information may, although unlikely, include information that may identify me personally.
- It is possible that even if the test identifies the underlying genetic cause for the disease in your family, this information may not help in predicting the progression of disease or change management or treatment of disease.

FINANCIAL AGREEMENT AND GUARANTEE

By signing this consent form, I accept full and complete financial responsibility for all genetic testing ordered by my healthcare provider. For insurance billing, I hereby authorize Baylor Genetics to bill my health insurance plan on my behalf, and further authorize Baylor Genetics to release any information to my insurance carrier which is reasonably required for billing. I additionally designate Baylor Genetics as my designated representative for purposes of appealing any denial of benefits by my insurance carrier. I irrevocably assign associated payment to Baylor Genetics, and direct that payment be made directly to Baylor Genetics. I understand that my out-of-pocket costs may be different than the estimated amount indicated to me by Baylor Genetics as part of a verification of benefits investigation. I agree to be financially responsible for all amounts as indicated on the explanation of benefits issued by my health insurance plan. If my insurance provider sends a payment directly to me for unpaid services performed by Baylor Genetics on my behalf, I agree to endorse the insurance check as appropriate and forward such check to Baylor Genetics within thirty (30) days of receipt thereof, as payment towards Baylor Genetics' claim for services rendered. If I do not have health insurance, I agree to pay for the full cost of the genetic testing that was ordered by my healthcare provider and billed to me by Baylor Genetics.

I understand that a completed Advance Beneficiary Notice (ABN) is required for Medicare patients if the service is deemed not medically necessary.

RECONTACT FOR RESEARCH CONSENT

Baylor Genetics participates in research relating to health, disease prevention, drug development, and other scientific purposes. Baylor Genetics may contact patients or their provider(s) directly as part of this research. I agree to allow Baylor Genetics to contact me or my provider(s) about possible research involving the sample(s) and/or information associated with this testing. I understand that patients generally receive no compensation for this participation in research. For more information on research at Baylor Genetics, please visit baylorgenetics.com.

If I wish to opt out of being recontacted for research purposes by Baylor Genetics, I understand that I may check the box below:

☐ Please do not contact me regarding any research that uses information obtained from this testing.

For any research I may be contacted about, I prefer contact through the following methods (please check all that apply – if no choices are selected, contact will be made via secure email if possible):

☐ Email ☐ Phone ☐ Mail



INFORMED CONSENT FOR INHERITED EYE DISORDERS TESTING

Patient Last Name Patient First Name MI Date of Birth (MM / DD / YYYY) Genetic Sex

PATIENT AUTHORIZATION

By signing this statement of consent, I acknowledge that I have read, understand, and hereby grant my informed consent for genetic testing. I have received appropriate explanations from my healthcare provider about the planned genetic test(s) and possible results. I have been informed by my healthcare provider about the availability and importance of genetic counseling and have been provided with written information identifying a genetic counselor or medical geneticist who can provide such counseling services. All my questions have been answered and I have had the necessary time to make an informed decision about the genetic test(s).

I hereby give permission to Baylor Genetics to conduct genetic testing as recommended by my physician.

Patient's Printed Name Patient's Signature Date (MM / DD / YYYY)

Patient's Parent / Personal Representative* Name Patient's Parent / Personal Representative Signature Date (MM / DD / YYYY)

Relationship of Personal Representative to the Patient Ordering Provider's Signature Date (MM / DD / YYYY)

*If you are signing as a person with legal authority to act on behalf of the patient, you may be required to provide evidence of your authority.